AMB-895 / Ambrosia Biosciences - LARVOL DELTA

Discovery of AMB-895, a Long-Acting and Novel, Oral Small Molecule GLP-1 Receptor Agonist (OBESITY WEEK 2026) - No abstract available

Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline (PRNewswire) - "Proceeds from the financing will support: Advancement of the Company's novel oral small molecule GLP-1 into a Phase 1 clinical trial; Continued development of the Company's other small molecule programs, including GIP and amylin."

Financing • Metabolic Disorders • Obesity